ASSEMBLY BIOSCIENCES, INC.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Christopher L. JacobsHouse · R · NY |
ASMBASSEMBLY BIOSCIENCES, INC. · Stock |
Sale $1,001 - $15,000 |
Feb 17, 2021 | Jan 4, 2021 | Filing ↗ |
Christopher L. JacobsHouse · R · NY |
ASMBASSEMBLY BIOSCIENCES, INC. · Stock |
Purchase $1,001 - $15,000 |
Feb 10, 2021 | Dec 28, 2020 | Filing ↗ |
Whale Activity
- Increased48
- New21
- Held15
- Decreased16
- Closed12
- No prior filing4
| Filer | Shares | Value | Change |
|---|---|---|---|
| GILEAD SCIENCES, INC. | 5.0M | $116.9M | held |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 1.6M | $37.7M | held |
| Paradigm Biocapital Advisors LP | 1.6M | $36.5M | held |
| BlackRock, Inc. | 1.5M | $35.0M | increased |
| RA CAPITAL MANAGEMENT, L.P. | 1.0M | $24.0M | held |
| Parkman Healthcare Partners LLC | 796.3K | $18.7M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 602.9K | $14.2M | increased |
| STATE STREET CORP | 559.6K | $13.1M | increased |
| MILLENNIUM MANAGEMENT LLC | 490.1K | $11.5M | increased |
| Commodore Capital LP | 461.9K | $10.9M | decreased |
| Seven Fleet Capital Management LP | 417.4K | $9.8M | decreased |
| CITADEL ADVISORS LLC | 379.8K | $8.9M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Bjorkquist Jeanette MPFO and PAO | Sale | −9 | $20.35 | $183 | Nov 2, 2026 | Form 4 ↗ |
| Bjorkquist Jeanette MPFO and PAO | Sale | −718 | $19.61 | $14K | Nov 2, 2026 | Form 4 ↗ |
| White Nicole SChief Manufacturing Officer | Sale | −29 | $20.35 | $590 | Nov 2, 2026 | Form 4 ↗ |
| White Nicole SChief Manufacturing Officer | Sale | −2,564 | $19.61 | $50K | Nov 2, 2026 | Form 4 ↗ |
| Gaggar AnujChief Medical Officer | Sale | −29 | $20.35 | $590 | Nov 2, 2026 | Form 4 ↗ |
| Gaggar AnujChief Medical Officer | Sale | −2,564 | $19.61 | $50K | Nov 2, 2026 | Form 4 ↗ |
| Okazaki Jason ACEO and President · Director | Sale | −69 | $20.35 | $1K | Nov 2, 2026 | Form 4 ↗ |
| Okazaki Jason ACEO and President · Director | Sale | −6,133 | $19.61 | $120K | Nov 2, 2026 | Form 4 ↗ |
| Bjorkquist Jeanette MPFO and PAO | Sale | −29 | $23.25 | $674 | Jun 17, 2026 | Form 4 ↗ |
| GILEAD SCIENCES, INC.10% owner | Grant / award | +471.7K | $26.50 | $12.5M | May 26, 2026 | Form 4 ↗ |
| Bjorkquist Jeanette MPFO and PAO | Sale | −16 | $27.49 | $440 | Mar 30, 2026 | Form 4 ↗ |
| Bjorkquist Jeanette MPFO and PAO | Sale | −312 | $26.65 | $8K | Mar 30, 2026 | Form 4 ↗ |
| White Nicole SChief Manufacturing Officer | Sale | −9 | $27.49 | $247 | Mar 30, 2026 | Form 4 ↗ |
| White Nicole SChief Manufacturing Officer | Sale | −188 | $26.65 | $5K | Mar 30, 2026 | Form 4 ↗ |
| Gaggar AnujChief Medical Officer | Grant / award | +14.0K | $0.00 | $0 | Mar 29, 2026 | Form 4 ↗ |
| White Nicole SChief Manufacturing Officer | Grant / award | +14.0K | $0.00 | $0 | Mar 29, 2026 | Form 4 ↗ |
| Bjorkquist Jeanette MPFO and PAO | Grant / award | +3,500 | $0.00 | $0 | Mar 29, 2026 | Form 4 ↗ |
| Delaney William E IVChief Scientific Officer | Grant / award | +14.0K | $0.00 | $0 | Mar 29, 2026 | Form 4 ↗ |
| Okazaki Jason ACEO and President · Director | Grant / award | +50.8K | $0.00 | $0 | Mar 29, 2026 | Form 4 ↗ |
| Bjorkquist Jeanette MPFO and PAO | Grant / award | +6,500 | $0.00 | $0 | Mar 29, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 413.3K | $11.4M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 245.0K | $6.7M | 0.01% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 133.3K | $3.7M | 0.00% | Jun 30, 2026 |
| abrdn Healthcare Investors | 129.7K | $3.6M | 0.26% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 107.4K | $2.7M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 89.3K | $2.5M | 0.02% | Jun 30, 2026 |
| abrdn Life Sciences Investors | 77.3K | $2.1M | 0.31% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 56.7K | $1.9M | 0.00% | Aug 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 56.4K | $1.9M | 0.01% | Aug 31, 2026 |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 41.0K | $1.0M | 0.09% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ASMB's shares (CUSIP 045396207), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- JANUS HENDERSON GROUP Ltd.SCHEDULE 13G/A · passive (13G) · 674.3K shares3.3%
Nov 16, 2026 · ↗ - Paradigm BioCapital International Fund Ltd.SCHEDULE 13G/A · passive (13G) · 1.4M shares6.9%
Aug 14, 2026 · ↗ - Senai Asefaw, M.D.SCHEDULE 13G/A · passive (13G) · 1.6M shares7.8%
Aug 14, 2026 · ↗ - Paradigm BioCapital Advisors GP LLCSCHEDULE 13G/A · passive (13G) · 1.6M shares7.8%
Aug 14, 2026 · ↗ - Paradigm BioCapital Advisors LPSCHEDULE 13G/A · passive (13G) · 1.6M shares7.8%
Aug 14, 2026 · ↗ - JANUS HENDERSON GROUP Ltd.SCHEDULE 13G/A · passive (13G) · 1.4M shares6.9%
Aug 13, 2026 · ↗ - Farallon Capital F5 Master I, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 4, 2026 · ↗ - Farallon Capital (AM) Investors, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 4, 2026 · ↗ - Farallon Capital Offshore Investors II, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 4, 2026 · ↗ - Four Crossings Institutional Partners V, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 4, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming ASSEMBLY BIOSCIENCES, INC. as the client.
Government Contracts
No federal contract awards found for ASSEMBLY BIOSCIENCES, INC..
U.S. Patents
No USPTO patent applications found for ASSEMBLY BIOSCIENCES, INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | n/a | n/a | n/a |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M | -$129.9M |
| Diluted EPS | -$0.55 | -$6.69 | -$13.38 | -$23.08 | -$3.00 |
| Operating cash flow | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M |
| Cash and equivalents | $58.5M | $38.3M | $19.8M | $52.4M | $45.6M |
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M |
| Shareholders' equity | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M |
As ASSEMBLY BIOSCIENCES, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 19, 2026 ↗
Stock Splits
- 1-for-12Reverse splitFeb 12, 2024
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
EDGAR ↗ - 8-K/A · Items 2.02, 9.01Results of operationsAug 14, 2026
EDGAR ↗ - 8-K · Items 2.01, 9.01Acquisition or dispositionAug 13, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 5, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsMay 26, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsMay 22, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗

